Is this an opportune moment to pick up shares in this FTSE 250 growth share?

With the share price down more than 25% today, is now the time to plunge in and buy some of this company’s shares?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I last wrote about cybersecurity solutions provider Sophos Group (LSE: SOPH) in July when the share price had plunged around 20% on the release of the first-quarter trading update. Earnings and business volumes had grown but fallen below expectations. The underlying growth story in the business was good, but the valuation was high, so all the pressure was on the downside.

I concluded that article by saying that even after the share-price fall, the forward price-to-earnings ratio (P/E) was around 50, which meant the shares weren’t cheap when measured against the “green-shoot” earnings the firm was posting. However, I thought there was a “tangible” growth story unfolding and was keen to keep an eye on the stock with “the idea of picking up a few shares at opportune moments.” Fast-forward and essentially, the share price moved sideways before plunging more than 25% today on the release of the half-year report. Let’s check back in to see what the company said.

Promising figures

At first glance, the figures look promising. Revenue grew almost 18% compared to the equivalent period the year before and profit before tax came in at $26m compared to a loss of $35.5m the year before. At constant currency rates, first-half billings rose 2%, and there was a “modest improvement” in operating cash flow and free cash flow against the comparative period. Last year, the firm did exceptionally well, so the directors described the comparator period as “tough.”

Chief executive Kris Hagerman explained in the report that Sophos is making “solid progress” with its strategy of delivering “advanced and highly effective” cybersecurity solutions to IT professionals at organisations of all sizes.  The firm saw ongoing growth in Sophos Central, its strategic cloud management platform, which now has over 77,000 customers. The firm is also “well on track” to release two significant upgrades to its flagship products, Intercept X with EDR, and XG Firewall v17.5, which aim to deliver synchronised security. The move should position Sophos well “in the market for next-generation security solutions, for H2 and beyond.”  

Well placed for future growth

The outlook is positive. Sophos thinks it is “well positioned” for future growth. There is a “strong” innovation pipeline and the firm is making a “significant” investment in its strategic Sophos Central cloud platform.  There should be a “modest” improvement in constant currency billings growth in the second half of the year compared to the first half. But the company reckons it is on course to deliver a “significant improvement” in the rate of overall constant currency year-on-year billings growth during 2020.

City analysts following the company have pencilled in earnings growth of around 14% for 2020. At today’s share price close to 339p, the forward P/E rating sits at 40 or so, which is an improvement on the rating of 50 back in July. However, I think speculation drove the shares too high before this firm was profitable. I believe there is a robust-looking growth story emerging in the underlying business and soon the valuation looks set to collide with the growth curve to form an attractive entry point – but I don’t think we are quite there yet, so I’ll watch from the sidelines a bit longer

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

This FTSE 100 Dividend Aristocrat is on sale now

Stephen Wright thinks Croda International’s impressive dividend record means it could be the best FTSE 100 stock to add to…

Read more »

Investing Articles

3 shares I’d buy for passive income if I was retiring early

Roland Head profiles three FTSE 350 dividend shares he’d like to buy for their passive income to support an early…

Read more »

Investing Articles

Here’s how many Aviva shares I’d need for £1,000 a year in passive income

Our writer has been buying shares of this FTSE 100 insurer, but how many would he need to aim for…

Read more »

Female Doctor In White Coat Having Meeting With Woman Patient In Office
Investing Articles

1 incredible growth stock I can’t find on the FTSE 100

The FTSE 100 offers us a lot of interesting investment opportunities, but there's not much in the way of traditional…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

With an £8K lump sum, I could create an annual second income worth £5,347

This Fool explains how a second income is achievable by using a lump sum, investing in stocks, and the magic…

Read more »

Investing Articles

Here’s what dividend forecasts could do for the BT share price in the next 3 years

With the BT share price down so low, the dividend looks very nice indeed. The company's debt is off-putting, though.…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

28% revenue growth per year and down over 20% in price! Should I invest in this niche FTSE 250 company?

Oliver says this FTSE 250 company has done an excellent job bringing auctioning into the modern world. Will he invest…

Read more »

Investing Articles

After gaining over 200% in 12 months, what’s next for Nvidia stock?

Oliver thinks Nvidia stock could be as enduring an investment as Amazon. Even given the valuation risks, he says he…

Read more »